Linqi Chen

Linqi Chen

Auto-generated profile, based on publicly available information

Linqi Chen

Department of Endocrinology, Genetics and Metabolism, Children's Hospital of Soochow University, Suzhou , Jiangsu

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2023 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
LHLing Hou
Ling Hou
KHKe Huang
Ke Huang
CGChunxiu Gong
Chunxiu Gong
FLFeihong Luo
Feihong Luo
WHwei haiyan
wei haiyan
Xiaoping LuoXiaoping Luo
Xiaoping Luo
Context The evidence of long-term polyethylene glycol recombinant human GH (PEG-rhGH) in pediatric GH deficiency (GHD) is limited. Objective This study aimed to examine the effectiveness and safety of long-term PEG-rhGH in children with GHD in the real world, as well as to examine the effects of dose on patient outcomes. Design A prospective, observational, posttrial study (NCT03290235). Setting, participants and intervention Children with GHD were enrolled from 81 centers in China in 4 individual clinical trials and received weekly 0.2 mg/kg/wk (high-dose) or 0.1 to <0.2 mg/kg/wk (low-dose) PEG-rhGH for 30 months. Main outcomes measures Height SD score (Ht SDS) at 12, 24, and 36 months. Results A total of 1170 children were enrolled in this posttrial study, with 642 patients in the high-dose subgroup and 528 in the low-dose subgroup. The Ht SDS improved significantly after treatment in the total population (P < 0.0001), with a mean change of 0.53 ± 0.30, 0.89 ± 0.48, 1.35 ± 0.63, 1.63 ± 0.75 at 6 months, 12 months, 24 months, and 36 months, respectively. In addition, the changes in Ht SDS from baseline were significantly improved in the high-dose subgroup compared with the low-dose subgroup at 6, 12, 24, and 36 months after treatment (all P < 0.05). A total of 12 (1.03%) patients developed serious adverse events. There was no serious adverse event related to the treatment, and no AEs leading to treatment discontinuation or death occurred. Conclusions PEG-rhGH showed long-term effectiveness and safety in treating children with GHD. Both dose subgroups showed promising outcomes, whereas PEG-rhGH 0.2 mg/kg/wk might show additional benefit.

4 February 2019 in Journal of the Endocrine Society
Verified
Journal Article
Open access
PDF file
HSHui Sun
Hui Sun
HWHaiying Wu
Haiying Wu
RXRongrong Xie
Rongrong Xie
FWFengyun Wang
Fengyun Wang
TCTing Chen
Ting Chen
LCLinqi Chen
Linqi Chen
We found a sporadic case of mental retardation, associated to short stature and constipation. We investigated the possible genetic origin of the syndrome. Clinical and biochemical investigations were conducted. Exome sequencing was used to search for pathogenic variations. A de novo mutation (c.1183G>T, p.E395X) was found in one allele of the THRA gene. The mutation creates a stop codon, which eliminates the C-terminal helix of the TRα1 receptor for thyroid hormone. The patient presents typical symptoms for the RTHα genetic disease, but has a normal head circumference. There are now 21 known mutations in THRA. All mutations which alter the C-terminal helix of TRα1 lead to severe forms of RTHα.

11 July 2020 in Human Mutation
Verified
Journal Article
Closed access
PDF file
LWLee‐Jun C. Wong
Lee‐Jun C. Wong
TCTing Chen
Ting Chen
ESEric S. Schmitt
Eric S. Schmitt
JWJing Wang
Jing Wang
STSha Tang
Sha Tang
WCWilliam J. Craigen
William J. Craigen

30 September 2020 in Experimental Biology and Medicine
Verified
Journal Article
Closed access
PDF file
TCTing Chen
Ting Chen
CCCailong Chen
Cailong Chen
HWHaiying Wu
Haiying Wu
XCXiuli Chen
Xiuli Chen
RXRongrong Xie
Rongrong Xie
LCLinqi Chen
Linqi Chen
High-fat intake and subsequent obesity are associated with premature onset of puberty, but the exact neuroendocrine mechanisms are still unclear. The transcriptional factor p53 has been predicted to be a central hub of the gene networks controlling the pubertal onset. Besides, p53 also plays crucial roles in metabolism. Here, we explored p53 in the hypothalami of mice fed a high-fat diet (HFD), which showed an up-regulated expression. Besides, we also revealed that overexpressed p53 may accelerate hypothalamo-pituitary-gonadal (HPG) axis activation partially through the c-Myc/Lin28/let-7 system. These results can deepen our understanding of the interaction between metabolic regulation and puberty onset control, and may shed light on the neuroendocrine mechanisms of obesity-related central precocious puberty.

28 March 2020 in BMC Pediatrics
Verified
Journal Article
Open access
PDF file
DWDi Wu
Di Wu
RCRuimin Chen
Ruimin Chen
SCShao-Ke Chen
Shao-Ke Chen
GLGe-Li Liu
Ge-Li Liu
LCLin-Qi Chen
Lin-Qi Chen
CGChunxiu Gong
Chunxiu Gong
Background: To evaluate the efficacy of GH in improving FAH in ISS children in a multicenter study. Methods: A real-world observation was carried out. Children with ISS in seven hospitals in China were enrolled. The height gains standard deviation score and the height gain over the target height were evaluated. Results: There were 344 ISS patients (217 boys and 127 girls). The baseline average age of boys and girls was 12.7 and 11.7 years, with bone age of 11.7 and 10.1 years, respectively. The baseline height SDS of boys and girls was − 3.07 and − 2.74, and the FAH SDS was − 1.91 and − 1.38, respectively. Compared with the baseline height SDS, the FAH SDS was significantly increased in both boys and girls (both P = 0.0000). The FAH SDS was the highest (gain by 1.54 SD) in the ≥2y treatment course group. Two hundred eighteen patients (218/344, 63.4%) had a FAH SDS > − 2 SD. Among these patients, girls in the 1-2y treatment course group and ≥ 2y group had a FAH SDS higher than TH SDS. Even in the control group, a spontaneous catch-up growth of 1.16 SD was observed. A multivariate linear regression model was used to analyze the results, with FAH SDS as the dependent variable. It was found that the treatment course and baseline height SDS in the boys’ model were statistically significant (P < 0.05), whereas the baseline height SDS and baseline bone age significantly affected the girls’ FAH SDS (P < 0.05). Conclusions: Both girls and boys of ISS improved FAH by GH therapy even if treatments begin over 10 years old and majority of them reached TH. Some peri-puberty ISS will have a spontaneous height gain. We recommend the course of GH treatment more than 2 years for girls, and longer courses for boys.

1 September 2019 in Diabetes, Metabolic Syndrome and Obesity
Verified
Journal Article
Open access
PDF file
TCTing Chen
Ting Chen
FWFengyun Wang
Fengyun Wang
ZCZhenyu Chu
Zhenyu Chu
XSXiaoyan Shi
Xiaoyan Shi
LSLing Sun
Ling Sun
MHMiao Hou
Miao Hou
Purpose: CTRP3 is a novel peptide that has recently emerged as an important regulatory adipokine of obesity and related metabolic disease. Little is known about its role in children. The current study aimed to investigate the potential role of CTRP3 in obese children and explore its relationships with insulin sensitivity, pancreatic β cell function, and obesity-related markers. Patients and methods: We studied the levels of serum CTRP3 in 48 obese and 36 normal weight pre-puberty children. The levels of blood pressure, lipids, glucose, and insulin were measured, and the values of HOMA-IR, HOMA-β and insulinogenic index were calculated. The correlations of these measurements with CTRP3 levels were analyzed. Results: In this study, we found that CTRP3 serum levels significantly decreased in obese children compared to controls, and insulin resistant obese subjects have lower CTRP3 levels in contrast with the non-insulin resistant obese subjects. Moreover, serum CTRP3 concentrations significantly decreased, while glucose and insulin concentrations significantly increased after a 3 hrs oral glucose tolerance test in obese children. Furthermore, Serum CTRP3 levels correlated negatively and significantly with BMI, triglycerides, systolic blood pressure, fasting insulin, glucose, HOMA-IR, HOMA-β and insulinogenic index in obese children. Conclusion: In summary, serum CTRP3 levels significantly decreased in obese children, and negatively correlated with insulin resistance and pancreatic β cell function indicators. Therefore, CTRP3 may play a protective role in the glucose homeostasis and tightly related to β cell function as well as obesity-related markers in obese children.